Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 216

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 216
---
 we owned patents in various jurisdictions, including one patent in China, expiring in 2041. We also had patent applications pending in various jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2041.

HMPL-A83 - The intellectual property portfolio for HMPL-A83 as of December 31, 2024 is summarized below:

We had a first patent family directed to novel anti-CD47 antibodies as well as methods of treating cancers with such antibodies. In this patent family, we had patent applications pending in various jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2041.

We had a second patent family directed to the formulation of HMPL-A83. In this patent family, we had patent applications pending in China, which, if issued, would have an expiration date in 2042.

HMPL-415 - The intellectual property portfolio for HMPL-415 as of December 31, 2024 is summarized below:

We had a patent family directed to novel small molecule compounds as well as methods of treating cancers, Noonan Syndrome and LEOPARD Syndrome with such compounds. In this patent family, we had patent applications pending in various jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2042.

HMPL-506 - The intellectual property portfolio for HMPL-506 as of December 31, 2024 is summarized below:

We had a patent family directed to novel small molecule compounds as well as methods of treating cancers with such compounds. In this patent family, we had PCT, Argentina and Taiwan patent applications pending, each of which, if issued, would have an expiration date in 2043.

Other Ventures Patents

As of December 31, 2024, our joint venture Shanghai Hutchison Pharmaceuticals had (i) 86 patents in China, (ii) three patents in Canada, one patent in the U. S. and one patent in Japan granted under the Patent Cooperation Treaty, and (iii) 49 pending Chinese patent applications and 11 patent applications under the Patent Cooperation Treaty, among them, two of which were filed in China, including patents for its key prescription products described below.

Table of Contents

She Xiang Bao Xin Pills. As of December 31, 2024, Shanghai Hutchison Pharmaceuticals held an invention patent in